WakeMed

Summary

WakeMed is a medical facility located in Raleigh, North Carolina. This center is recognized for care of Coronary Artery Disease, Heart Failure, Stroke, Myocardial Ischemia, Atherosclerosis and other specialties. WakeMed is involved with conducting 92 clinical trials across 141 conditions. There are 9 research doctors associated with this hospital, such as Judson B Williams, MD, Frances Wood, MD, Stuart Russell, MD, and Saroj Neupane, MD.

Top PIs

Clinical Trials running at WakeMed

Stroke

Kidney Failure

Heart Failure

Chronic Kidney Disease

High Blood Pressure

Chronic Renal Failure

Renal Disease

Hemorrhage

Atrial Fibrillation

Difficult Intubation

Anticoagulation + Antiplatelet Therapy

for Post-Operative Atrial Fibrillation

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.

Recruiting

2 awards

Phase 3

2 criteria

Non-Invasive Device

for Traumatic Brain Injury

The purpose of this research, which has been determined as non-significant risk by the central IRB overseeing the study, is to obtain information to help further develop a machine (a medical device) to measure the pressure around the brain from the outside (this pressure is called intracranial pressure or ICP). Monitoring and managing ICP is an important part of care for patients with conditions such as Traumatic Brain Injury (TBI). However, the current way of measuring ICP requires surgery to drill a hole into the skull, and therefore can introduce additional risks such as infections and pain. Recent research has shown it may be possible to measure ICP without needing surgery. This technology is in development, but large amounts of data is required to build these new devices. Through collecting a large database of information from patients who have both the routine surgical device and the research device applied to their head, the research team will work to develop and test an effective and potentially safer way of monitoring patient ICP.

Recruiting

1 award

N/A

4 criteria

BB-031

for Stroke

The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset. Participants will be randomized to receive one dose of either the investigational drug or placebo and will be followed for 90 days. A total of 228 patients are planned in this study.

Recruiting

0 awards

Phase 2

4 criteria